Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The last earnings update was 64 days ago. More info.
Add to Portfolio Compare Print
SUNPHARMA Share Price and Events
7 Day Returns
1 Year Returns
SUNPHARMA Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries (SUNPHARMA) | -2% | -0.7% | 8.4% | -9.7% | -44.2% | -26.1% |
| IN Pharmaceuticals | 0.8% | 1.3% | 0.8% | 1.1% | -11.2% | 37.8% |
| IN Market | 1.2% | 2.8% | 5.7% | -0% | 41.8% | 73.7% |
1 Year Return vs Industry and Market
- SUNPHARMA underperformed the Pharmaceuticals industry which returned 1.1% over the past year.
- SUNPHARMA underperformed the Market in India which returned -0% over the past year.
SUNPHARMA Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Sun Pharmaceutical Industries
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Sun Pharmaceutical Industries.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 24 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 14.8% |
| Perpetual Growth Rate | 10-Year IN Government Bond Rate | 7.6% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year IN Govt Bond Rate | 7.6% |
| Equity Risk Premium | S&P Global | 8.6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.73 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.726 (1 + (1- 35%) (9.66%)) |
0.847 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.85 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.847 * 8.6%) |
14.84% |
Discounted Cash Flow Calculation for NSEI:SUNPHARMA using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Sun Pharmaceutical Industries is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (INR, Millions) | Source |
Present Value Discounted (@ 14.84%) |
|
|---|---|---|---|
| 2019 | 41,725.88 | Analyst x8 | 36,335.10 |
| 2020 | 42,059.69 | Analyst x13 | 31,893.92 |
| 2021 | 53,222.08 | Analyst x13 | 35,144.27 |
| 2022 | 58,210.96 | Est @ 9.37% | 33,472.52 |
| 2023 | 63,349.00 | Est @ 8.83% | 31,720.81 |
| 2024 | 68,697.94 | Est @ 8.44% | 29,954.99 |
| 2025 | 74,314.37 | Est @ 8.18% | 28,217.54 |
| 2026 | 80,250.50 | Est @ 7.99% | 26,534.75 |
| 2027 | 86,555.39 | Est @ 7.86% | 24,921.96 |
| 2028 | 93,276.03 | Est @ 7.76% | 23,387.25 |
| Present value of next 10 years cash flows | ₹301,583.11 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= ₹93,276.03 × (1 + 7.55%) ÷ (14.84% – 7.55%) |
₹1,376,812.99 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= ₹1,376,812.99 ÷ (1 + 14.84%)10 |
₹345,210.51 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= ₹301,583.11 + ₹345,210.51 |
₹646,793.62 |
| Equity Value per Share (INR) |
= Total value / Shares Outstanding
= ₹646,793.62 / 2,399.33 |
₹269.57 |
| Calculation | Result | |
|---|---|---|
| Value per share (INR) | From above. | ₹269.57 |
| Current discount | Discount to share price of
₹462.55
= -1 x (₹462.55 - ₹269.57) / ₹269.57 |
-71.6% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Sun Pharmaceutical Industries is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Sun Pharmaceutical Industries's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Sun Pharmaceutical Industries's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in INR | ₹14.33 |
| NSEI:SUNPHARMA Share Price ** | NSEI (2019-04-16) in INR | ₹462.55 |
| India Pharmaceuticals Industry PE Ratio | Median Figure of 112 Publicly-Listed Pharmaceuticals Companies | 20.36x |
| India Market PE Ratio | Median Figure of 2,735 Publicly-Listed Companies | 16.29x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Sun Pharmaceutical Industries.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NSEI:SUNPHARMA Share Price ÷ EPS (both in INR) = 462.55 ÷ 14.33 |
32.28x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sun Pharmaceutical Industries is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Sun Pharmaceutical Industries is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does
Sun Pharmaceutical Industries's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 32.28x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 24 Analysts |
31%per year |
| India Pharmaceuticals Industry PEG Ratio | Median Figure of 32 Publicly-Listed Pharmaceuticals Companies | 1.39x |
| India Market PEG Ratio | Median Figure of 585 Publicly-Listed Companies | 1.32x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 32.28x ÷ 31% |
1.04x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sun Pharmaceutical Industries is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Sun Pharmaceutical Industries's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in INR | ₹170.60 |
| NSEI:SUNPHARMA Share Price * | NSEI (2019-04-16) in INR | ₹462.55 |
| India Pharmaceuticals Industry PB Ratio | Median Figure of 133 Publicly-Listed Pharmaceuticals Companies | 1.89x |
| India Market PB Ratio | Median Figure of 3,625 Publicly-Listed Companies | 1.12x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NSEI:SUNPHARMA Share Price ÷ Book Value per Share (both in INR) = 462.55 ÷ 170.60 |
2.71x |
* Primary Listing of Sun Pharmaceutical Industries.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sun Pharmaceutical Industries is overvalued based on assets compared to the IN Pharmaceuticals industry average.
Value checks
We assess Sun Pharmaceutical Industries's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Sun Pharmaceutical Industries has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
SUNPHARMA Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Sun Pharmaceutical Industries's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
- Sun Pharmaceutical Industries's earnings growth is expected to exceed the India market average.
- Sun Pharmaceutical Industries's revenue growth is positive but not above the India market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NSEI:SUNPHARMA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 24 Analysts | 31% |
| NSEI:SUNPHARMA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 24 Analysts | 11.6% |
| India Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 20.6% |
| India Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 13.5% |
| India Market Earnings Growth Rate | Market Cap Weighted Average | 18.7% |
| India Market Revenue Growth Rate | Market Cap Weighted Average | 11.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 24 Analyst Estimates (S&P Global) | See Below |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 369,931 | 66,557 | 60,078 | 22 |
| 2020-03-31 | 333,621 | 55,965 | 50,316 | 24 |
| 2019-03-31 | 295,404 | 49,571 | 32,300 | 23 |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 288,052 | 34,379 | |
| 2018-09-30 | 277,182 | 24,380 | |
| 2018-06-30 | 275,048 | 35,690 | |
| 2018-03-31 | 264,155 | 39,072 | 21,616 |
| 2017-12-31 | 263,811 | 20,763 | |
| 2017-09-30 | 276,530 | 31,827 | |
| 2017-06-30 | 295,310 | 45,057 | |
| 2017-03-31 | 313,081 | 70,822 | 69,644 |
| 2016-12-31 | 319,185 | 73,270 | |
| 2016-09-30 | 311,431 | 74,000 | |
| 2016-06-30 | 297,512 | 61,937 | |
| 2016-03-31 | 281,086 | 66,859 | 45,457 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 24 Analyst Estimates (S&P Global) | See Below |
All data from Sun Pharmaceutical Industries Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 24.85 | 27.10 | 21.40 | 20.00 |
| 2020-03-31 | 20.88 | 22.70 | 18.60 | 22.00 |
| 2019-03-31 | 13.68 | 18.00 | 10.62 | 12.00 |
| Date (Data in INR Millions) | EPS * |
|---|---|
| 2018-12-31 | 14.33 |
| 2018-09-30 | 10.16 |
| 2018-06-30 | 14.86 |
| 2018-03-31 | 9.01 |
| 2017-12-31 | 8.73 |
| 2017-09-30 | 13.18 |
| 2017-06-30 | 18.82 |
| 2017-03-31 | 28.98 |
| 2016-12-31 | 30.50 |
| 2016-09-30 | 30.68 |
| 2016-06-30 | 25.81 |
| 2016-03-31 | 18.89 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Sun Pharmaceutical Industries is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Future performance checks
We assess Sun Pharmaceutical Industries's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Sun Pharmaceutical Industries has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
SUNPHARMA Past Performance
How has Sun Pharmaceutical Industries performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Sun Pharmaceutical Industries's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Sun Pharmaceutical Industries's 1-year earnings growth exceeds its 5-year average (65.6% vs -5.7%)
- Sun Pharmaceutical Industries's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (65.6% vs 16.4%).
Earnings and Revenue History
All data from Sun Pharmaceutical Industries Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 288,051.70 | 34,378.90 | 58,539.30 | |
| 2018-09-30 | 277,182.10 | 24,380.40 | 57,315.80 | |
| 2018-06-30 | 275,048.40 | 35,689.80 | 54,701.80 | |
| 2018-03-31 | 264,155.40 | 21,615.50 | 54,814.30 | |
| 2017-12-31 | 263,811.10 | 20,762.90 | 54,007.40 | |
| 2017-09-30 | 276,529.90 | 31,827.20 | 52,432.10 | |
| 2017-06-30 | 295,309.70 | 45,057.40 | 49,928.80 | |
| 2017-03-31 | 313,081.40 | 69,643.70 | 50,284.70 | |
| 2016-12-31 | 319,185.20 | 73,270.10 | 49,985.90 | |
| 2016-09-30 | 311,430.50 | 74,000.40 | 49,212.30 | |
| 2016-06-30 | 297,512.10 | 61,937.20 | 48,012.00 | |
| 2016-03-31 | 281,086.10 | 45,457.10 | 49,076.30 | |
| 2015-12-31 | 266,280.70 | 38,914.60 | 95,368.90 | |
| 2015-09-30 | 264,669.60 | 28,701.90 | 94,999.60 | |
| 2015-06-30 | 276,422.20 | 38,149.70 | 45,608.30 | |
| 2015-03-31 | 273,920.10 | 45,393.80 | 46,483.20 | |
| 2014-12-31 | 170,764.60 | 59,141.40 | 45,585.90 | |
| 2014-09-30 | 170,835.10 | 60,201.60 | 45,035.90 | |
| 2014-06-30 | 165,250.30 | 58,100.00 | 44,680.40 | |
| 2014-03-31 | 160,803.60 | 31,414.70 | 44,040.40 | |
| 2013-12-31 | 150,932.90 | 26,103.80 | 35,071.00 | |
| 2013-09-30 | 136,587.10 | 19,606.00 | 33,778.30 | |
| 2013-06-30 | 120,629.30 | 9,364.10 | 16,867.50 | |
| 2013-03-31 | 112,998.60 | 29,895.90 | 30,506.00 | |
| 2012-12-31 | 105,114.30 | 28,178.20 | 25,640.90 | |
| 2012-09-30 | 98,111.70 | 26,048.10 | 24,654.40 | |
| 2012-06-30 | 90,280.80 | 28,818.00 | 12,603.30 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Sun Pharmaceutical Industries has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Sun Pharmaceutical Industries used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Sun Pharmaceutical Industries's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Sun Pharmaceutical Industries's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Sun Pharmaceutical Industries has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
SUNPHARMA Health
How is Sun Pharmaceutical Industries's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Sun Pharmaceutical Industries's finances.
The net worth of a company is the difference between its assets and liabilities.
- Sun Pharmaceutical Industries is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sun Pharmaceutical Industries's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Sun Pharmaceutical Industries Company Filings, last reported 3 months ago.
| Date (Data in INR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 454,302.70 | 107,184.30 | 149,907.20 |
| 2018-09-30 | 454,302.70 | 107,184.30 | 149,907.20 |
| 2018-06-30 | 419,847.20 | 110,895.10 | 144,995.50 |
| 2018-03-31 | 419,847.20 | 103,852.70 | 141,362.50 |
| 2017-12-31 | 409,361.60 | 114,226.00 | 153,518.10 |
| 2017-09-30 | 409,361.60 | 114,226.00 | 153,518.10 |
| 2017-06-30 | 404,305.30 | 80,910.00 | 155,975.70 |
| 2017-03-31 | 404,305.30 | 98,317.70 | 154,470.50 |
| 2016-12-31 | 403,971.70 | 82,954.30 | 141,734.50 |
| 2016-09-30 | 403,971.70 | 82,954.30 | 141,734.50 |
| 2016-06-30 | 354,901.40 | 83,381.00 | 147,045.30 |
| 2016-03-31 | 370,677.30 | 84,967.60 | 139,125.60 |
| 2015-12-31 | 315,024.50 | 70,377.50 | 141,453.60 |
| 2015-09-30 | 315,024.50 | 70,377.50 | 141,453.60 |
| 2015-06-30 | 293,582.00 | 75,963.40 | 131,154.70 |
| 2015-03-31 | 284,892.80 | 90,073.10 | 131,154.70 |
| 2014-12-31 | 243,507.40 | 3,139.20 | 80,066.80 |
| 2014-09-30 | 243,507.40 | 3,139.20 | 80,066.80 |
| 2014-06-30 | 204,461.30 | 25,637.20 | 95,886.10 |
| 2014-03-31 | 204,461.30 | 25,637.20 | 95,886.10 |
| 2013-12-31 | 184,504.30 | 27,041.90 | 85,982.40 |
| 2013-09-30 | 184,504.30 | 27,041.90 | 85,982.40 |
| 2013-06-30 | 157,798.20 | 1,982.10 | 53,639.30 |
| 2013-03-31 | 166,248.10 | 2,621.10 | 53,639.30 |
| 2012-12-31 | |||
| 2012-09-30 | |||
| 2012-06-30 | 133,278.00 | 2,649.90 | 49,911.00 |
- Sun Pharmaceutical Industries's level of debt (23.6%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (14.6% vs 23.6% today).
- Debt is well covered by operating cash flow (36.5%, greater than 20% of total debt).
- Sun Pharmaceutical Industries earns more interest than it pays, coverage of interest payments is not a concern.
Financial health checks
We assess Sun Pharmaceutical Industries's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Sun Pharmaceutical Industries has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
SUNPHARMA Dividends
What is Sun Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
₹2,000 of
Sun Pharmaceutical Industries
shares you are expected to receive
₹9
in your first year as a dividend.
Dividend Amount
- Sun Pharmaceutical Industries's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.49%).
- Sun Pharmaceutical Industries's dividend is below the markets top 25% of dividend payers in India (1.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 24 Analyst Estimates (S&P Global) | See Below |
| India Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 69 Stocks | 0.7% |
| India Market Average Dividend Yield | Market Cap Weighted Average of 1399 Stocks | 1.3% |
| India Minimum Threshold Dividend Yield | 10th Percentile | 0.3% |
| India Bottom 25% Dividend Yield | 25th Percentile | 0.5% |
| India Top 25% Dividend Yield | 75th Percentile | 1.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in ₹) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-03-31 | 3.15 | 22.00 |
| 2020-03-31 | 2.96 | 23.00 |
| 2019-03-31 | 2.57 | 23.00 |
| Date (Data in ₹) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2018-09-26 | 2.000 | 0.423 |
| 2017-09-04 | 3.500 | 0.646 |
| 2016-08-18 | 1.000 | 0.158 |
| 2016-05-30 | 1.000 | 0.128 |
| 2015-10-07 | 3.000 | 0.368 |
| 2014-08-13 | 1.500 | 0.170 |
| 2014-08-12 | 1.500 | 0.189 |
| 2013-08-08 | 2.500 | 0.413 |
| 2012-08-10 | 2.125 | 0.530 |
| 2012-08-08 | 2.125 | 0.630 |
| 2011-05-30 | 1.750 | 0.658 |
| 2010-06-14 | 1.375 | 0.671 |
| 2010-05-24 | 1.375 | 0.829 |
| 2009-04-20 | 1.375 | 0.990 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Dividends per share have increased over the past 10 years.
Income/ dividend checks
We assess Sun Pharmaceutical Industries's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Sun Pharmaceutical Industries afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Sun Pharmaceutical Industries has a total score of 3/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
SUNPHARMA Management
CEO
| COMPENSATION | ₹33,608,800 |
| AGE | 63 |
CEO Bio
Mr. Dilip Shantilal Shanghvi has been the Chairman and Managing Director of Sun Pharma Advanced Research Company Limited since March 1, 2012. Mr. Shanghvi Founded Sun Pharmaceutical Industries Limited in 1982 and serves as its Managing Director since May 29, 2012 and is its founding partner. As the promoter of SPIL, he has been actively involved in international pharmaceutical markets, business strategy, business development and research and development functions in it. Mr. Shanghvi served as the Chairman and Managing Director of Sun Pharmaceutical Industries, Inc. He has wide extensive industrial experience in the Pharmaceutical industry. He has been the Chairman of Taro Pharmaceutical Industries Ltd., since July 18, 2013. Mr. Shanghvi has been the Chairman of Sun Pharmaceutical Industries Inc. since 1997. Mr. Shanghvi served as the Chairman of the Board of Sun Pharmaceutical Industries Ltd until May 28, 2012. since 1999. He served as the Chairman of the Board of Taro Pharmaceutical Industries Ltd. from September 20, 2010 to April 18, 2012. He has been a Director of Sun Pharma Advanced Research Company Limited since March 1, 2006. He serves as a Director at Sun Speciality Chemicals Pvt. Ltd., Sun Resins & Polymers Pvt. Ltd., Sun Fastfin Services Pvt. Ltd., Sun Petrochemicals Private Limited, SPARC Bio-Research Private Limited, Sun Pharma Global Inc., British Virgin Island, Sun Pharma De Mexico SA DE CV, SPIL De Mexico SA DE CV and Shantilal Shanghvi Foundation. He serves as an Executive Director of Sun Pharmaceutical Industries Ltd. since March 01, 1993. He served as a Director of Taro Pharmaceutical Industries Ltd., until April 18, 2012. He also held Directorships in Alfa Infraprop Private Limited and Aditya Clean Power Ventures Private Limited. Mr. Shanghvi is a recipient of several awards as listed below: Lifetime Outstanding Achievement Award - IMA - 2018, Entrepreneur of the year Award - AIMA - 2017, Padma Shri – 2016 (Fourth Highest Civilian Award – Government of India), NDTV Business Leadership Award – Pharmaceutical – 2016, JRD Tata Corporate Leadership Award AIMA (All India Management Association) 2014, Economic Times Business Leader of the Year Award 2014, CNBC-TV18, Outstanding Business Leader of the Year 2014, Forbes Entrepreneur for the Year 2014, World Entrepreneur of the Year- Ernst and Young 2011, Indian of the Year (Business) CNN IBN 2011, Businessman of the Year- Business India 2011, Entrepreneur of the Year- Ernst and Young 2010, Entrepreneur of the Year- Economic Times 2008, CEO of the Year Business Standard 2008, First Generation Entrepreneur of the Year- CNBC TV 18 2007, Pharmaceutical Company IMC Juran Quality Medal 2007 and Entrepreneur of the Year (Healthcare and Life Sciences) Ernst and Young 2005. Mr. Shanghvi is graduate in commerce from Kolkata University.
CEO Compensation
- Dilip's compensation has been consistent with company performance over the past year.
- Dilip's remuneration is lower than average for companies of similar size in India.
Management Team Tenure
Average tenure and age of the Sun Pharmaceutical Industries management team in years:
- The tenure for the Sun Pharmaceutical Industries management team is about average.
Management Team
Dilip Shanghvi
MD & Executive Director
₹34M
63
C. Muralidharan
Chief Financial Officer
₹29M
55
1.8 yrs
Sailesh Desai
Whole Time Director
₹14M
64
Sudhir Valia
Whole Time Director
₹34M
62
Kal Subramanian
CEO of India Business and Emerging Markets & Whole-Time Director
64
2.2 yrs
Sunil Ajmera
Company Secretary
₹13M
8 yrs
Arun Sawhney
President
63
Govind Jaju
President and Global Head of Technical Operations
Indrajit Banerjee
President
62
Ashok Bhuta
Senior General Manager - Secretarial & Compliance Officer
Board of Directors Tenure
Average tenure and age of the Sun Pharmaceutical Industries board of directors in years:
- The tenure for the Sun Pharmaceutical Industries board of directors is about average.
Board of Directors
Israel Makov
Non-Executive Director & Chairman
₹900K
79
6.9 yrs
Dilip Shanghvi
MD & Executive Director
₹34M
63
26.1 yrs
Sailesh Desai
Whole Time Director
₹14M
64
20.1 yrs
Sudhir Valia
Whole Time Director
₹34M
62
14.2 yrs
Kal Subramanian
CEO of India Business and Emerging Markets & Whole-Time Director
64
2.2 yrs
Rekha Sethi
Non-Executive Independent Director
₹1M
55
5.2 yrs
Vivek Sehgal
Additional Independent Director
₹300K
62
1.4 yrs
Gautam Doshi
Non-Executive Independent Director
65
0.9 yrs
Who owns this company?
Recent Insider Trading
- Sun Pharmaceutical Industries insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (₹) | Value (₹) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10. Apr 19 | Sell | Pratham Investments | Company | 01. Apr 19 | 01. Apr 19 | -50,000 | ₹482.26 | ₹-24,113,153 | ||
| 10. Apr 19 | Sell | Jayant Sanghvi | Individual | 02. Apr 19 | 02. Apr 19 | -25,000 | ₹479.02 | ₹-11,975,523 | ||
| 01. Apr 19 | Sell | Pratham Investments | Company | 20. Mar 19 | 29. Mar 19 | -190,227 | ₹479.80 | ₹-90,828,835 | ||
| 20. Mar 19 | Sell | Pratham Investments | Company | 14. Mar 19 | 19. Mar 19 | -362,119 | ₹472.34 | ₹-152,461,069 | ||
| 20. Mar 19 | Sell | Jayant Sanghvi | Individual | 14. Mar 19 | 15. Mar 19 | -377,881 | ₹464.83 | ₹-175,261,891 | ||
| 14. Mar 19 | Sell | Jayant Sanghvi | Individual | 11. Mar 19 | 13. Mar 19 | -500,000 | ₹470.91 | ₹-232,113,730 | ||
| 23. Jan 19 | Buy | Rakesh Mehta | Individual | 18. Jan 19 | 18. Jan 19 | 6,000 | ₹379.51 | ₹2,277,060 | ||
| 14. Dec 18 | Sell | Rita Desai | Individual | 13. Dec 18 | 13. Dec 18 | -38,200 | ₹425.25 | ₹-16,244,548 | ||
| 07. Dec 18 | Sell | Rajinder Jalali | Individual | 26. Nov 18 | 26. Nov 18 | -7,772 | ₹510.00 | ₹-3,963,720 | ||
| 20. Nov 18 | Sell | Nayna Daptardar | Individual | 12. Sep 18 | 12. Sep 18 | -3,000 | ₹619.78 | ₹-1,859,341 | ||
| 20. Nov 18 | Buy | Nayna Daptardar | Individual | 14. Nov 18 | 14. Nov 18 | 3,000 | ₹525.17 | ₹1,575,504 | ||
| 04. Dec 18 | Sell | Nayna Daptardar | Individual | 30. Nov 18 | 30. Nov 18 | -5,500 | ₹491.75 | ₹-2,704,607 | ||
| 04. Dec 18 | Buy | Nayna Daptardar | Individual | 27. Nov 18 | 27. Nov 18 | 3,000 | ₹486.02 | ₹1,458,060 | ||
| 26. Oct 18 | Sell | Rita Desai | Individual | 23. Oct 18 | 23. Oct 18 | -15,000 | ₹574.65 | ₹-8,619,749 | ||
| 21. Sep 18 | Sell | Jayant Sanghvi | Individual | 12. Sep 18 | 18. Sep 18 | -531,097 | ₹670.26 | ₹-352,309,178 | ||
| 12. Sep 18 | Sell | Jayant Sanghvi | Individual | 05. Sep 18 | 11. Sep 18 | -197,632 | ₹674.13 | ₹-130,960,725 | ||
| 12. Sep 18 | Sell | Jayant Sanghvi | Individual | 03. Sep 18 | 11. Sep 18 | -622,632 | ₹680.27 | ₹-418,756,783 | ||
| 10. Sep 18 | Sell | Jitendra Valia | Individual | 07. Sep 18 | 07. Sep 18 | -3,500 | ₹665.87 | ₹-2,330,545 | ||
| 06. Sep 18 | Sell | Jitendra Valia | Individual | 05. Sep 18 | 05. Sep 18 | -3,500 | ₹669.29 | ₹-2,342,515 | ||
| 04. Sep 18 | Sell | Jitendra Valia | Individual | 03. Sep 18 | 03. Sep 18 | -1,500 | ₹669.49 | ₹-1,004,235 | ||
| 04. Sep 18 | Sell | Pratham Investments | Company | 27. Aug 18 | 31. Aug 18 | -100,100 | ₹623.11 | ₹-62,373,308 | ||
| 04. Sep 18 | Sell | Jayant Sanghvi | Individual | 29. Aug 18 | 31. Aug 18 | -268,500 | ₹654.94 | ₹-173,155,790 | ||
| 03. Sep 18 | Sell | Jitendra Valia | Individual | 31. Aug 18 | 31. Aug 18 | -8,500 | ₹653.28 | ₹-5,552,880 | ||
| 31. Aug 18 | Sell | Jitendra Valia | Individual | 30. Aug 18 | 30. Aug 18 | -10,000 | ₹637.09 | ₹-6,370,900 | ||
| 28. Aug 18 | Sell | Jitendra Valia | Individual | 23. Aug 18 | 23. Aug 18 | -100 | ₹644.90 | ₹-64,490 | ||
| 28. Aug 18 | Sell | Pratham Investments | Company | 20. Aug 18 | 24. Aug 18 | -1,095,200 | ₹641.45 | ₹-691,094,049 | ||
| 23. Aug 18 | Sell | Jitendra Valia | Individual | 21. Aug 18 | 21. Aug 18 | -6,000 | ₹635.92 | ₹-3,815,520 | ||
| 06. Aug 18 | Sell | Rita Desai | Individual | 01. Aug 18 | 01. Aug 18 | -6,000 | ₹571.61 | ₹-3,429,660 | ||
| 04. Aug 18 | Sell | Pratham Investments | Company | 30. Jul 18 | 02. Aug 18 | -1,000,000 | ₹580.40 | ₹-567,085,802 | ||
| 01. Aug 18 | Sell | Rita Desai | Individual | 26. Jul 18 | 26. Jul 18 | -5,000 | ₹559.84 | ₹-2,799,200 | ||
| 30. Jul 18 | Sell | Pratham Investments | Company | 26. Jul 18 | 27. Jul 18 | -302,378 | ₹557.05 | ₹-168,167,690 | ||
| 26. Jul 18 | Sell | Pratham Investments | Company | 23. Jul 18 | 25. Jul 18 | -225,000 | ₹561.72 | ₹-125,989,995 | ||
| 28. Jun 18 | Sell | Pratham Investments | Company | 25. Jun 18 | 25. Jun 18 | -10,000 | ₹571.80 | ₹-5,718,000 | ||
| 25. Jun 18 | Sell | Pratham Investments | Company | 18. Jun 18 | 18. Jun 18 | -10,000 | ₹576.75 | ₹-5,767,499 | ||
Management checks
We assess Sun Pharmaceutical Industries's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Sun Pharmaceutical Industries has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
SUNPHARMA News
Simply Wall St News
Is Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) 9.6% ROE Strong Compared To Its Industry?
To keep the lesson grounded in practicality, we'll use ROE to better understand Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA). … One way to conceptualize this, is that for each ₹1 of shareholders' equity it has, the company made ₹0.096 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleWho Are The Major Shareholders In Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)?
In this analysis, my focus will be on developing a perspective on Sun Pharmaceutical Industries Limited’s (NSE:SUNPHARMA) latest ownership structure, a less discussed, but important factor. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Simply Wall St - – Full articleIs Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Attractive At Its Current PE Ratio?
While this makes SUNPHARMA appear like a stock to avoid or sell if you own it, you might change your mind after I explain the assumptions behind the P/E ratio. … I will explain what the P/E ratio is as well as what you should look out for when using it … What you need to know about the P/E ratio
Simply Wall St - – Full articleWhy Are Insiders Bearish About Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Stock?
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. … Sun Pharmaceutical Industries is one of India’s. … some insider selling over the past three months, with insiders divesting from.
Simply Wall St - – Full articleHow Did Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) 6.21% ROE Fare Against The Industry?
and want to begin learning the link between Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)’s return fundamentals and stock market performance. … Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) delivered a less impressive 6.21% ROE over the past year, compared to the 10.69% return generated by its industry. … Knowing these components can change your views on SUNPHARMA's below-average returns
Simply Wall St - – Full articleWhat Are Analysts Saying About Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Long Term Outlook?
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) most recent earnings update in March 2018a … headwind with earnings
Simply Wall St - – Full articleIntrinsic Calculation For Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Shows Investors Are Overpaying
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) as an investment opportunity. … by taking the expected future cash flows and discounting them to their present value. … If you are reading this and its not June 2018 then I highly recommend you check out the latest calculation for Sun Pharmaceutical Industries by following the link below.
Simply Wall St - – Full articleWhat Should We Expect From Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Earnings In The Next Couple Of Years?
Investors may find it useful to understand how market analysts perceive Sun Pharmaceutical Industries's earnings growth trajectory over the next couple of years and whether the future looks brighter. … View our latest analysis for Sun Pharmaceutical Industries Market analysts' consensus outlook for this coming year seems positive, with earnings climbing by a significant 97.41%. … This means, we can expect Sun Pharmaceutical Industries will grow its earnings by 36.19% every year for the next couple of years.
Simply Wall St - – Full articleWhat Kind Of Risk Should You Expect For Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … SUNPHARMA's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns. … Thus, we can expect SUNPHARMA to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleWhat Investors Should Know About Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Financial Strength
On top of this, SUNPHARMA has produced cash from operations of ₹70.82B over the same time period, leading to an operating cash to total debt ratio of 72.03%, indicating that SUNPHARMA’s current level of operating cash is high enough to cover debt. … SUNPHARMA’s level of debt is appropriate relative to its total equity, at 27.90%. … Next Steps: SUNPHARMA’s high cash coverage and appropriate debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow.
Simply Wall St - – Full articleSUNPHARMA Company Info
Description
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, dermatology, gynaecology, vitamins/minerals/nutrients, respiratory, ophthalmology, orthopaedic, and nephrology. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. Sun Pharmaceutical Industries Limited was founded in 1983 and is based in Mumbai, India.
Details
| Name: | Sun Pharmaceutical Industries Limited |
| SUNPHARMA | |
| Exchange: | NSEI |
| Founded: | 1983 |
| ₹1,109,812,390,373 | |
| 2,399,334,970 | |
| Website: | http://www.sunpharma.com |
| Address: |
Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Mumbai, Maharashtra, 400063, India |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NSEI | SUNPHARMA | Equity Shares | National Stock Exchange of India | IN | INR | 09. Feb 1995 | |
| BSE | 524715 | Equity Shares | Mumbai Stock Exchange | IN | INR | 09. Feb 1995 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/17 12:54 |
| End of day share price update: | 2019/04/16 00:00 |
| Last estimates confirmation: | 2019/04/16 |
| Last earnings filing: | 2019/02/12 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
